Upcoming Plans
- COVID-19 Impact: All research was shut down for several months but has gradually ramped up again with trainees restricted to 60% occupancy at SickKids. New and existing projects, pre-clinical ones in particular, were put on hold. Planning for potential future clinical trials has continued and discussions are ongoing with teams in the US and UK.
- Supported by curtisfund, results of the NANT study for MIBG therapy which randomised MIBG on its own against MIBG with other agents to make the neuroblastoma more radiosensitive have been presented publicly. Routine MIBG standard of care has been updated to offer treatment with the ‘winning’ drug (vorinostat) that appears to make the MIBG more effective - allowing children to immediately benefit from this research finding
- Plan to start a new MIBG study together with another class of chemotherapy drug (PARP inhibitors). Discussions with drug companies and medical teams in the US and UK are ongoing to pave the way for a clinical trial that curtisfund will support.